Meticulous Research®,
leading global market research company published a research report titled, “The
Global Molecular Cytogenetics Market is
projected to reach $2,266.4 million by 2022 growing at a CAGR of 11.0% during
the forecast period of 2017 to 2022.”
This
growth is primarily driven by the increasing focus on preventive healthcare
measures, increasing genetic abnormalities; growing aging population and subsequent
increase in chronic diseases, increasing need to reduce mounting healthcare
cost, and rising focus on clinical and research diagnosis.
Molecular cytogenetics plays an
important role in diagnosis of various diseases. Based on the type of diseases,
the diagnosis can be possible using various cytogenetic techniques such as
Fluorescence In Situ Hybridization (FISH), In Situ Hybridization, Karyotyping,
Banding Techniques, and others. The banding techniques have been used since
past decades because of their easy accessibility and availability. However, due
to its drawbacks in identifying genetic diseases at submicroscopic level, it is
further modified into in situ hybridization. Currently, the FISH plays a major
role in diagnosis of various diseases at genetic level using advanced molecular
cytogenetic products.
FISH is mainly used to detect the
chromosomal aberrations such as deletion, duplication, insertion, and gene
expression. It can be applicable to any specimen. Also, it is suitable for
heterogeneous breakpoints or multiple translocation patterns. However, it has
less sensitivity for detecting the genetic abnormality and requires expertise
to interpret the results as there is a risk of getting false positive results.
However, with the growing need to diagnose diseases at molecular level,
array-based technologies have emerged and preferred over FISH technique.
Read full
Research Report Study On
Array based techniques are preferred
over FISH since the high resolution, locus specific analysis, and genome wide
evaluation are combined in a single technique. Also, the sensitivity of these
techniques is high compared to FISH which is useful for researchers in the
detection of microdeletions. The array-based techniques are used in detection
of any type of cancers since they are able to screen whole genome variations
compared to FISH. The microarray uses 1000 probes at a time, whereas FISH uses
only one probe. The use of these many probes at a time makes the diagnosis easy
and quick. This technique is also useful in the detection of abnormalities in
all 24 chromosomes, whereas FISH has limit up to 12 chromosomes.
The report provides
meticulous analysis of Molecular
Cytogenetics Market on the basis of technique
(fluorescence in situ hybridization, comparative genomic hybridization, in situ
hybridization, karyotyping, and banding techniques), product (instruments, kits
and reagents, software, services, and consumable/accessories), application
(oncology, genetic disorders, personalized medicines, and other), end user
(pharmaceuticals and biotechnological companies, clinical and diagnostic
laboratories, and academic institutes), and geography.
The use of array is mostly in detection
of copy number variations which is not applicable for FISH. Thus, because of
the number of benefits provided by array-based techniques, their use by various
end users is increasing for both qualitative and quantitative detection of
genetic diseases. These techniques not only improve the sensitivity of
diagnosis but also the accuracy of results. This transition helps in use of
diagnostic products to large extent.
The major companies such as Thermo
Fisher Scientific, Illumina Inc., Agilent Technologies, and Oxford Gene
Technology are manufacturing array-based products in order to accelerate
research. They are providing sophisticated technology for running thousands of
samples at a time to analyze genetic variations efficiently.
Hurry Up To Get Your Free Sample Report
Now!
The key players analyzed in the
molecular cytogenetics market are Thermo Fisher Scientific (U.S.), Abbott
Laboratories (U.S.), Agilent Technologies (U.S.), PerkinElmer (U.S.), Bio-Rad
Laboratories (U.S.), Applied Spectral Imaging (U.S.), Quest Diagnostics (U.S.),
Roche Diagnostics (Switzerland) , Danaher Corporation (U.S.), Illumina (U.S.),
and Oxford Gene Technology (U.S.).
Contact
-
Viren Shrivastava
Email: viren@meticulousresearch.com
Direct Lines: +1-646-781-8004 (North
America)
+91 744-7780008 (Asia-Pacific)
No comments:
Post a Comment